Success Stories
Highlights of the PCI news focused on Penn commercialization accomplishments
Highlights of the PCI news focused on Penn commercialization accomplishments
The company was awarded FDA orphan drug designation for its experimental therapy, GTP-506, on the heels of the drug receiving rare pediatric disease designation.
This fall, the Penn Center for Innovation and Penn Engineering present three monthly sessions with expert speakers, who will discuss funding, pitching, and open source software for commercialization.
This fall, the Penn Center for Innovation and Penn Medicine present three monthly speaker sessions with experts in the field of Life Sciences investing, university startups, and intellectual property.
Tumors within the heart affect thousands of patients around the world annually, but prior to the ŌNŌ system, open-heart surgery was the only way to remove them.
Lumify Care and Neuralert have grown rapidly in terms of funding and product expansion.
Shinkei Systems cuts down on waste by reducing the likelihood that off-target species would be caught and killed, and streamlining the process to avoid waste.
Rosa's experience working in the lab and participating in the PCI Fellows program at Penn helped her gain valuable experience for her career at Deloitte.
Learn about Marion Leary and her mission to help health professionals pursue a career path in innovation.
PCI Fellows get exposure to a wide range of emerging technologies and commercialization opportunities in the life sciences, physical sciences, nanotechnology, and beyond.
In a proof-of-concept study, a robotic microswarm of nanoparticles, arranged in bristle-like structures, effectively cleaned plaque and decay-causing bacteria from both mock and human teeth.